EVM
ATRA icon

Eaton Vance Management’s Atara Biotherapeutics ATRA Stock Holding History

Eaton Vance Management’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-3,161
Closed -$2.75M – 1236
2018
Q4 		$2.75M Buy
3,161
+1,209
+62% +$1.12M 0.01% 638
2018
Q3 		$2.02M Hold
1,952
– – ﹤0.01% 763
2018
Q2 		$1.79M Buy
+1,952
New +$2.1M ﹤0.01% 761

Other funds holding ATRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Eaton Vance Management's ATRA Position: Q1 2019 in Review

Eaton Vance Management sold out of Atara Biotherapeutics (ATRA) in Q1 2019, closing a stake of 3,161 shares — an estimated $2.75M sold.

Eaton Vance Management first reported a position in ATRA in Q2 2018 and held it in 3 quarters. The position peaked at $2.75M in Q4 2018. 120 funds tracked by Wall St. Rank hold ATRA as of Q1 2019.

  • Eaton Vance Management reported no remaining Atara Biotherapeutics position as of Q1 2019 after selling out during the quarter.
  • Eaton Vance Management sold 3,161 Atara Biotherapeutics shares in Q1 2019, an estimated $2.75M.
  • Eaton Vance Management first reported a position in Atara Biotherapeutics in Q2 2018 and held it in 3 quarters.
  • Eaton Vance Management's Atara Biotherapeutics position peaked at $2.75M in Q4 2018.
  • 120 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2019.

Based on Eaton Vance Management's 13F filing for Q1 2019, filed 14 May 2019.